Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
| Country | United States |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Vishwas Seshadri |
Contact Details
Address: 6555 Carnegie Avenue, 4th Floor Cleveland, Ohio 44103 United States | |
| Phone | 646 813 4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vishwas Seshadri | Chief Executive Officer |
| Joseph Vazzano | Chief Financial Officer |
| Gregory Gin | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 29, 2025 | 144 | Filing |
| Jan 21, 2025 | 144 | Filing |
| Jan 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | DEF 14A | Other definitive proxy statements |